LOGIN
ID
PW
MemberShip
2025-02-07 05:25
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Drug expenditures surge due to the use of high-priced drugs
by
Lee, Tak-Sun
Jan 17, 2025 05:53am
Drug expenditures have risen significantly in 2023 due to the rising cost of high-priced anticancer drugs and rare disease treatments. Due to the aging population increasing the expenditures spent on treating chronic diseases, an urgent need has arisen to come up with a measure to reduce drug expenditures. According to the National Health Ins
Company
Expanded reimb for 'Zejula'
by
Son, Hyung Min
Jan 17, 2025 05:53am
Following the reimbursement expansion of Zejula for ovarian cancer, patient access to treatment has been improved. Experts suggest that Zejula will be more widely used in clinical practices based on demonstrated benefits in efficacy and safety in long-term treatment studies. On January 16, Takeda Pharmaceutical Korea held a press conferen
Policy
Pulmonary fibrosis drug 'Ofev' under consideration for reimb
by
Lee, Tak-Sun
Jan 17, 2025 05:53am
As 'Ofev Soft cap (nintedanib),' a treatment for pulmonary fibrosis, has been approved for reimbursement appropriateness, latecomer drugs are projected to enter the market quickly. Following the expiration of Ofev's usage patent, latecomer companies are anticipated to prepare for launching their drugs. According to industry sources on J
Policy
Innovative Pharmaceutical Company certification to change
by
Lee, Jeong-Hwan
Jan 17, 2025 05:53am
The Ministry of Health and Welfare will improve the certification system for innovative pharmaceutical companies to a 'certification evaluation score system' that will increase the proportion of new drug research and development (R&D) and change the disqualification criteria to a point-based score system. The MOHW plans to issue an admin
Company
Ultomiris is reimbursed for aHUS in Korea
by
Son, Hyung Min
Jan 16, 2025 06:14am
Ultomiris has been reimbursed in Korea for atypical hemolytic uremic syndrome (aHUS) since January. While experts have welcomed the news of its reimbursement, they have also raised the need for systematic improvements to the stringent conditions for reimbursement, including the preliminary review requirement. On the 10th, AstraZeneca Kore
Company
Last year's pharma export sales recorded KRW 11T
by
Kim, Jin-Gu
Jan 16, 2025 06:14am
Last year's export sales of Korea-made pharmaceuticals amounted to US$ 7.5 billion (approximately KRW 11 trillion), up 29% from the previous year. Analysis indicates that a significant increase in biopharmaceutical exports of Samsung Biologics and Celltrion has contributed to the growth. The largest exported country was the United State
Company
Elahere receives orphan drug designation in Korea
by
Eo, Yun-Ho
Jan 16, 2025 06:13am
The new ovarian cancer drug Elahere has received an orphan drug designation in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced the designation through the first orphan drug designation announcement of the new year. Specifically, the drug is indicated as monotherapy in adult patients with folate receptor-alpha (FR
Company
Companies develop new drugs for Fabry disease
by
Son, Hyung Min
Jan 16, 2025 06:13am
Domestic and foreign pharmaceutical companies are speeding up the development of new drugs for the rare Fabry disease. They aim to develop treatments that improve not only efficacy and safety but also administration methods compared to existing treatments. According to industry sources on the 15th, the Ministry of Food and Drug Safety rec
Company
JW Pharma's hemophilia assay for patients using 'Hemlibra'
by
Kim, Jin-Gu
Jan 16, 2025 06:13am
JW Pharmaceutical announced on January 15 that its chromogenic assay designed to assess the severity of 'hemophilia' in patients using 'Hemlibra' has been commercialized in South Korea. The Ministry of Health and Welfare (MOHW) has newly established a non-reimbursable CSA testing criterion, effective January 1. CSA test is used to m
Company
China-made new drugs actively enter the global market
by
Son, Hyung Min
Jan 16, 2025 06:13am
Many Chinese pharmaceutical and biotech companies are demonstrating results from their new anti-cancer drug development in the global market. Companies like Jiangsu Hengrui Pharmaceuticals and BeiGene have obtained approvals for their immunotherapy and targeted anti-cancer agents from the regulatory authorities globally, including South Korea, t
1
2
3
4
5
6
7
8
9
10
>